Prime Medicine
Prime Medicine Inc is an American clinical-stage biotechnology enterprise headquartered in Cambridge, Massachusetts. The company specializes in the development of next-generation gene editing therapies, anchored by its proprietary 'Prime Editing' technology platform, designed to precisely correct genetic mutations and treat a wide range of inherited diseases. Principal revenue is currently earned through strategic research collaborations, grant funding, and capital financing arrangements as clinical pipelines advance. Prime Medicine is publicly listed on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Prime Medicine.
- Legal name
- Prime Medicine Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
- Exposure themes
- Gene Editing, Genetic Medicine, Precision Medicine & Genomics
Funds holding Prime Medicine
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)